8-K - Lifeloc Technologies, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Lifeloc Technologies, Inc. reported financial results for the fiscal year ended December 31, 2025, announcing 6% revenue growth to $9.027 million. The company disclosed a net loss of $2.470 million, significantly impacted by a non-cash deferred tax valuation allowance charge of $1.738 million.

Key Takeaways

1Revenue increased 6% to $9.027 million for the year ended December 31, 2025, compared to $8.538 million in 2024.

2Net loss widened to $2.470 million, or $0.90 per diluted share, compared to a net loss of $1.053 million, or $0.41 per diluted share, in 2024.

3A non-cash charge of $1.738 million was recorded for increased valuation allowance for deferred taxes in 2025, up from $187 thousand in 2024.

4Gross margin remained stable at 40.3% for 2025 compared to 40.4% for 2024.

5Cash and cash equivalents decreased to $746,001 as of December 31, 2025, from $1,243,746 at the end of 2024.

6The company reported progress on its SpinDetect™ Centrifugal Drug Analyzer, with production mold fabrication targeted for Q1 2026.

Current Report Details

Event Type

Financial Results

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

2.02

Results of Operations and Financial Condition. On March 27, 2026, Lifeloc Technologies, Inc. (the “Company”) issued a press release announcing its operating res

Financial Results

9.01

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated March 27, 2026, issued by the Company 104 Cover Page Interact

Exhibits Only

Source Document

Results of Operations

Fiscal Year 2025

Metric	Value	Prior Period
Revenue	$9.03	$8.54
Net Loss	$-2.47	$-1.05
Net Loss Per Share Diluted	$-0.90	$-0.41
Gross Margin	40.3%	40.4%
Operating Loss	$-1.23	$-1.41

Exhibits (2)

8-K

FORM 8-K

99.1

EXHIBIT 99.1